Growth Hormone Secretagogue MK-0677 Effect on IGF-1 Levels in ESRD Patients

NCT00395291 · clinicaltrials.gov ↗

NA

Phase

COMPLETED

Status

49

Enrollment

OTHER

Sponsor class

Conditions

Chronic Kidney Disease
End Stage Renal Disease

Interventions

DRUG: MK-0677
DRUG: Placebo

Sponsor

University of Virginia

Collaborators

[object Object]
[object Object]